Altered postprandial motility in chronic pancreatitis: Role of malabsorption

doi:10.1016/S0016-5085(97)70045-3

Gastroenterology

Volume 112, Issue 5, May 1997, Pages 1624-1634

https://doi.org/10.1016/S0016-5085(97)70045-3 Get rights and content

Abstract

BACKGROUND & AIMS: Intraileal nutrients modulate gastrointestinal motility, but effects of maldigestion on postprandial motility are unknown. The aim of this study was to compare motor responses with ileal nutrient exposure in health and pancreatic insufficiency after a meal or intraluminal perfusion. METHODS: After oroileal multilumen intubation for duodeno-jejuno-ileal sampling, marker perfusion, and motility recording, 14 normal subjects and 12 patients with severe pancreatic insufficiency received a labeled liquid meal twice, either with placebo or pancreatin. Effects of intraileal nutrient perfusion on fed motility induced by duodenal amino acid perfusion were also investigated. RESULTS: Compared with normals, untreated patients had greater cumulative ileal nutrient delivery (69 +/- 21 vs. 487 +/- 232 kJ), shorter fed pattern (196 +/- 22 vs. 131 +/- 14 minutes), greater 90% gastric emptying (163 +/- 12 vs. 128 +/- 10 minutes), and faster small intestinal transit (86 +/- 9 vs. 44 +/- 6 minutes). Pancreatin reversed these changes. Ileal nutrient perfusion converted fed into interdigestive-like motility in normals (7 of 8) and patients (4 of 5). CONCLUSIONS: In subjects with pancreatic insufficiency, a low-energy liquid meal induces shorter fed motor pattern associated with accelerated gastric emptying and intestinal transit compared with healthy subjects. Because changes responded to enzyme treatment and could be reproduced by ileal nutrient perfusion, ileal delivery of malabsorbed chyme may be involved as a mechanism. (Gastroenterology 1997 May;112(5):1624-34)

References (0)

Cited by (80)

ESPEN practical guideline on clinical nutrition in acute and chronic pancreatitis
2024, Clinical Nutrition
Both acute and chronic pancreatitis are frequent diseases of the pancreas, which, despite being of benign nature, are related to a significant risk of malnutrition and may require nutritional support. Acute necrotizing pancreatitis is encountered in 20 % of patients with acute pancreatitis, is associated with increased morbidity and mortality, and may require artificial nutrition by enteral or parenteral route, as well as additional endoscopic, radiological or surgical interventions. Chronic pancreatitis represents a chronic inflammation of the pancreatic gland with development of fibrosis. Abdominal pain leading to decreased oral intake, as well as exocrine and endocrine failure are frequent complications of the disease. All of the above represent risk factors related to malnutrition. Therefore, patients with chronic pancreatitis should be considered at risk, screened and supplemented accordingly. Moreover, osteoporosis and increased facture risk should be acknowledged in patients with chronic pancreatitis, and preventive measures should be considered.
ESPEN guideline on clinical nutrition in acute and chronic pancreatitis
2020, Clinical Nutrition
Citation Excerpt :
Untreated PEI has also a deleterious impact on the quality of life of patients [151]. As the quantitative measurement of fecal fat is often omitted, it is recommended that enzyme replacement is started when clinical signs of malabsorption, or anthropometric and/or biochemical signs of malnutrition are present [96,127,152–154]. Symptoms include weight loss, alteration of body compartments at bioimpedance analysis, and low nutritional markers (albumin, cholinesterase, prealbumin, retinol-binding protein, and magnesium) [127].
Both acute and chronic pancreatitis are frequent diseases of the pancreas, which, despite being of benign nature, are related to a significant risk of malnutrition and may require nutritional support. Acute necrotizing pancreatitis is encountered in 20% of patients with acute pancreatitis, is associated with increased morbidity and mortality, and may require artificial nutrition by enteral or parenteral route, as well as additional endoscopic, radiological or surgical interventions. Chronic pancreatitis represents a chronic inflammation of the pancreatic gland with development of fibrosis. Abdominal pain leading to decreased oral intake, as well as exocrine and endocrine failure are frequent complications of the disease. All of the above represent risk factors related to malnutrition. Therefore, patients with chronic pancreatitis should be considered at risk, screened and supplemented accordingly. Moreover, osteoporosis and increased facture risk should be acknowledged in patients with chronic pancreatitis, and preventive measures should be considered.
Etiopathogenesis and pathophysiology of chronic pancreatitis
2019, Transplantation, Bioengineering, and Regeneration of the Endocrine Pancreas: Volume 2
Chronic pancreatitis is an irreversible fibro-inflammatory disease of the pancreas that leads to progressive loss of exocrine and endocrine functions. Other consequences of chronic pancreatitis include severe abdominal pain, narcotic dependence, and poor quality of life. The etiologies of chronic pancreatitis include toxic (alcohol or smoking), genetic/hereditary, autoimmune, metabolic abnormalities, obstructive, and idiopathic. The pathophysiology of chronic pancreatitis is also complex and differs by etiology. Various mechanisms for the development and progression of chronic pancreatitis have been postulated but the actual process is still not clearly understood. The process involves injury to the acinar cells, followed by inflammation and repair in some cases, and in other cases, the inflammation persists to create a chronic environment. This chronic inflammatory environment activates the pancreatic stellate cells that play a vital role in causing fibrosis. Several molecular events have also been shown to be involved in the pathogenesis of the disease. This chapter will discuss the various etiologies, pathophysiologies and molecular events that lead to chronic pancreatitis.
Dysbiosis in benign and malignant diseases of the exocrine pancreas
2019, Microbiome and Metabolome in Diagnosis, Therapy, and other Strategic Applications
The consequences of dysbiosis in pancreatic diseases remain unclear, with a limited body of evidence suggesting that there may be an association between dysbiosis and pancreatic disease; however, some of the studies show contradictory results. Regarding acute and chronic pancreatitis, data are scarce, but dysbiosis appears to be present in both conditions. Some studies show lower levels of Bifidobacterium or Lactobacillus and higher levels of Enterobacteriaceae in chronic pancreatitis. One study shows higher levels of Enterococcus and lower levels of Bifidobacterium in acute pancreatitis. There is stronger evidence of a link between microbiota imbalance and pancreatic cancer. There is an overall association between pancreatic cancer and lower levels of Neisseria elongate and Streptococcus mitis and higher levels of Porphyromonas gingivalis and Granulicatella adiacens. However, further investigation is required to confirm these findings, and to explore clinical implications such as screening and therapeutic possibilities.
The potential role of gut microbiota in pancreatic disease: A systematic review
2017, Pancreatology
Citation Excerpt :
Furthermore, rupture of the gut barrier and the systemic inflammatory response secondary to cytokine release in both AP and CP, increases bacterial translocation. Both abnormal motility and bacterial translocation are also factors linked to bacterial overgrowth (SIBO) that occur in CP patients [32–34]. It is reasonable to posit that CP patients with overgrowth of bacteria into the small bowel may also have colonic microbiota imbalance, as malabsorption secondary to PEI has a significant impact on the nutrient absorption, and therefore on the availability of nutrients for intestinal microorganisms, and hence microbial composition of the gut.
Several studies have suggested a link between microbiota imbalance and some gastrointestinal, inflammatory and neoplastic diseases. However, the role in pancreatic diseases remain unclear. To evaluate the available evidence for pancreatic diseases, we undertook a systematic review.
OVID Medline (1946–2017), EMBASE (1980–2017) and the Cochrane Central Register of Controlled Trials (CENTRAL Issue 3, 2017) were searched for studies on microbiota in pancreatic disease. We also searched the reference lists of retrieved papers, and conference proceedings. We excluded animal studies, reviews, and case reports.
A total of 2833 articles were retrieved. After screening and applying the exclusion criteria, 10 studies were included. Three studies showed lower levels of Bifidobacterium or Lactobacillus and higher levels of Enterobacteriaceae in chronic pancreatitis. Two of these studies were uncontrolled, and the third (controlled) study which compared patients with endocrine and exocrine insufficiency, reported that Bacteroidetes levels were lower in those patients without diabetes, while Bifidobacteria levels were higher in those without exocrine insufficiency. Only one study investigated acute pancreatitis, showing higher levels of Enterococcus and lower levels of Bifidobacterium versus healthy participants. There was an overall association between pancreatic cancer and lower levels of Neisseria elongate, Streptococcus mitis and higher levels of Porphyromonas gingivalis and Granulicatella adiacens.
Current evidence suggests a possible link between microbiota imbalance and pancreatic cancer. Regarding acute and chronic pancreatitis, data are scarce, dysbiosis appears to be present in both conditions. However, further investigation is required to confirm these findings and to explore therapeutic possibilities.
Pancreatic exocrine insufficiency in pancreatic cancer: A review of the literature
2015, Digestive and Liver Disease
Pancreatic exocrine insufficiency is a well-documented complication of chronic pancreatitis; however, study results of pancreatic exocrine insufficiency in pancreatic cancer are less consistent. This applies for patients who are treated non-surgically and those who undergo curative pancreatic cancer resection.
This review article summarizes relevant studies addressing pancreatic exocrine insufficiency in pancreatic cancer, with particular differentiation between non-surgically and surgically treated patients, as well as between the different surgeries. We also summarize studies addressing pancreatic enzyme replacement therapy in pancreatic cancer.

View all citing articles on Scopus

View full text